ADC Therapeutics SA Debt to Equity Ratio 2019-2022 | ADCT

Current and historical debt to equity ratio values for ADC Therapeutics SA (ADCT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. ADC Therapeutics SA debt/equity for the three months ending March 31, 2022 was 0.68.
ADC Therapeutics SA Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.42B $0.16B 2.58
2021-12-31 $0.45B $0.17B 2.72
2021-09-30 $0.45B $0.19B 2.41
2021-06-30 $0.22B $0.24B 0.90
2021-03-31 $0.16B $0.30B 0.55
2020-12-31 $0.18B $0.34B 0.53
2020-09-30 $0.15B $0.38B 0.39
2020-06-30 $0.18B $0.20B 0.90
2020-03-31 $0.00B $0.00B 0.00
2019-12-31 $0.00B 0.00
2019-09-30 $0.00B $0.00B 0.00
2019-06-30 $0.00B $0.00B 0.00
2018-12-31 $0.02B $0.13B 0.19
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00